GSA Capital Partners LLP Invests $618,000 in Haemonetics Corporation $HAE

GSA Capital Partners LLP purchased a new stake in shares of Haemonetics Corporation (NYSE:HAE) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 12,675 shares of the medical instruments supplier’s stock, valued at approximately $618,000.

Several other hedge funds have also recently bought and sold shares of HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after buying an additional 971 shares during the last quarter. Caxton Associates LLP bought a new position in shares of Haemonetics in the 1st quarter valued at approximately $216,000. United Services Automobile Association acquired a new stake in Haemonetics in the 1st quarter worth approximately $212,000. Empowered Funds LLC boosted its position in Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after purchasing an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock valued at $9,923,000 after purchasing an additional 9,051 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Needham & Company LLC cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. Mizuho cut their target price on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a research report on Friday, February 6th. Barrington Research set a $94.00 price target on Haemonetics in a research report on Friday, February 6th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Finally, Robert W. Baird set a $81.00 target price on Haemonetics in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $84.44.

Haemonetics Trading Up 0.9%

Shares of HAE opened at $61.24 on Monday. The stock’s 50-day moving average price is $71.94 and its 200 day moving average price is $63.89. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 1.28 and a beta of 0.28. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.04. The company had revenue of $338.97 million for the quarter, compared to analyst estimates of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.Haemonetics’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, research analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.